image
ESSA Pharma Inc. EPIX
Healthcare - Biotechnology - NASDAQ - CA
Watchlist
$ 1.72
-2.27 %
$ 76.3 M
Market Cap
-2.77
P/E
1. INTRINSIC VALUE

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.[ Read More ]

The intrinsic value of one EPIX stock under the base case scenario is HIDDEN Compared to the current market price of 1.72 USD, ESSA Pharma Inc. is HIDDEN

EPIX Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart EPIX

image
FINANCIALS
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-32.1 M OPERATING INCOME
9.08%
Growth Rates
1Year 9.08%
3Years -11.61%
5Years -24.36%
7Years -7.29%
10Years -37.17%
-26.6 M NET INCOME
24.27%
Growth Rates
1Year 24.27%
3Years -4.27%
5Years -17.98%
7Years -10.59%
10Years -168.38%
-19.8 M OPERATING CASH FLOW
31.08%
Growth Rates
1Year 31.08%
3Years -5.22%
5Years -14.12%
7Years -3.74%
10Years -176.28%
-3.53 M INVESTING CASH FLOW
93.26%
Growth Rates
1Year 93.26%
3Years 45.46%
5Years -77.29%
7Years -131.22%
10Years 0.00%
-68.2 K FINANCING CASH FLOW
-26.97%
Growth Rates
1Year -26.97%
3Years -0.05%
5Years -0.06%
7Years -0.04%
10Years 0.00%
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-8.64 M OPERATING INCOME
17.68%
Growth Rates
1Year 9.08%
3Years -11.61%
5Years -24.36%
7Years -7.29%
10Years -37.17%
-7.23 M NET INCOME
19.53%
Growth Rates
1Year 24.27%
3Years -4.27%
5Years -17.98%
7Years -10.59%
10Years -168.38%
-5.75 M OPERATING CASH FLOW
16.57%
Growth Rates
1Year 31.08%
3Years -5.22%
5Years -14.12%
7Years -3.74%
10Years -176.28%
23.5 K INVESTING CASH FLOW
-99.96%
Growth Rates
1Year 93.26%
3Years 45.46%
5Years -77.29%
7Years -131.22%
10Years 0.00%
25.6 K FINANCING CASH FLOW
-96.05%
Growth Rates
1Year -26.97%
3Years -0.05%
5Years -0.06%
7Years -0.04%
10Years 0.00%
Balance Sheet Decomposition ESSA Pharma Inc.
image
Current Assets 149 M
Cash & Short-Term Investments 148 M
Receivables 135 K
Other Current Assets 585 K
Non-Current Assets 325 K
Long-Term Investments 0
PP&E 68 K
Other Non-Current Assets 257 K
Current Liabilities 3.5 M
Accounts Payable 2.03 M
Short-Term Debt 80.3 K
Other Current Liabilities 1.39 M
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall ESSA Pharma Inc.
image
Revenue 0
Cost Of Revenue 118 K
Gross Profit -118 K
Operating Expenses 32.1 M
Operating Income -32.1 M
Other Expenses -5.55 M
Net Income -26.6 M
RATIOS
0.00% GROSS MARGIN
0.00%
Averages
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years -3039.82%
0.00% OPERATING MARGIN
0.00%
Averages
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years -905161.29%
0.00% NET MARGIN
0.00%
Averages
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years -605529.95%
-18.25% ROE
-18.25%
Averages
1Year -18.25%
3Years -19.41%
5Years -21.81%
7Years -18.69%
10Years 203.02%
-17.83% ROA
-17.83%
Averages
1Year -17.83%
3Years -19.04%
5Years -21.05%
7Years -36.87%
10Years -54.22%
-22.07% ROIC
-22.07%
Averages
1Year -22.07%
3Years -20.72%
5Years -22.81%
7Years -72.65%
10Years 288.27%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ESSA Pharma Inc.
image
Net Income -26.6 M
Depreciation & Amortization 118 K
Capital Expenditures 0
Stock-Based Compensation 5.01 M
Change in Working Capital 2.34 M
Others 1.8 M
Free Cash Flow -19.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ESSA Pharma Inc.
image
Wall Street analysts predict an average 1-year price target for EPIX of $11.3 , with forecasts ranging from a low of $2 to a high of $17 .
EPIX Lowest Price Target Wall Street Target
2 USD 16.28%
EPIX Average Price Target Wall Street Target
11.3 USD 558.91%
EPIX Highest Price Target Wall Street Target
17 USD 888.37%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.

image
1.19 USD
CYTO
Undervalued 160.42%

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America.

image
-0.0706 USD
SMMT
Overvalued 100.39%

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain.

image
12.6 USD
ATXI
Undervalued 554.18%

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.

image
-0.715 USD
SPRO
Overvalued 160.61%
6. Ownership
Insider Ownership ESSA Pharma Inc.
image
Sold
0-3 MONTHS
12 M USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
16.6 K USD 1
9-12 MONTHS
782 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
154 K USD 2
9-12 MONTHS
Date Value Insider Amount Avg Price
2 weeks ago
Nov 01, 2024
Sell 3.06 M USD
BIOTECH GROWTH N V
10 percent owner
- 2000000
 1.532 USD
2 weeks ago
Nov 01, 2024
Sell 3.05 M USD
BIOTECH GROWTH N V
10 percent owner
- 2000000
 1.5259 USD
2 weeks ago
Nov 01, 2024
Sell 3.06 M USD
BIOTECH GROWTH N V
10 percent owner
- 2000000
 1.5294 USD
2 weeks ago
Nov 01, 2024
Sell 2.84 M USD
BIOTECH GROWTH N V
10 percent owner
- 1879583
 1.513 USD
2 months ago
Sep 09, 2024
Sell 4.16 K USD
Virsik Peter
Chief Operating Officer
- 694
 6 USD
2 months ago
Sep 03, 2024
Sell 12.6 K USD
Virsik Peter
Chief Operating Officer
- 2082
 6.03 USD
6 months ago
May 06, 2024
Sell 4.82 K USD
Virsik Peter
Chief Operating Officer
- 694
 6.95 USD
7 months ago
Apr 05, 2024
Sell 5.51 K USD
Virsik Peter
Chief Operating Officer
- 694
 7.94 USD
8 months ago
Mar 05, 2024
Sell 6.23 K USD
Virsik Peter
Chief Operating Officer
- 694
 8.98 USD
9 months ago
Feb 06, 2024
Sell 749 K USD
Virsik Peter
Chief Operating Officer
- 72782
 10.29 USD
9 months ago
Feb 05, 2024
Sell 6.42 K USD
Virsik Peter
Chief Operating Officer
- 694
 9.25 USD
9 months ago
Feb 05, 2024
Sell 5.02 K USD
Virsik Peter
Chief Operating Officer
- 500
 10.04 USD
10 months ago
Jan 16, 2024
Sell 17.2 K USD
Virsik Peter
Chief Operating Officer
- 1718
 10.01 USD
10 months ago
Jan 05, 2024
Sell 4.27 K USD
Virsik Peter
Chief Operating Officer
- 699
 6.11 USD
11 months ago
Dec 14, 2023
Bought 21.2 K USD
Parkinson David Ross
Chief Executive Officer
+ 9223
 2.3 USD
11 months ago
Nov 21, 2023
Bought 133 K USD
BERGER FRANKLIN M
Director
+ 23259
 5.73 USD
1 year ago
Nov 03, 2023
Bought 98.7 K USD
BERGER FRANKLIN M
Director
+ 16471
 5.99 USD
1 year ago
Nov 02, 2023
Bought 321 K USD
BERGER FRANKLIN M
Director
+ 60000
 5.35 USD
1 year ago
Dec 30, 2022
Bought 7.97 K USD
Parkinson David Ross
Chief Executive Officer
+ 3067
 2.6 USD
1 year ago
Dec 22, 2022
Bought 51.1 K USD
Parkinson David Ross
Chief Executive Officer
+ 21367
 2.39 USD
1 year ago
Dec 14, 2022
Sell 75 K USD
BERGER FRANKLIN M
Director
- 25000
 3 USD
1 year ago
Dec 15, 2022
Sell 92.8 K USD
BERGER FRANKLIN M
Director
- 32000
 2.9 USD
1 year ago
Dec 15, 2022
Sell 143 K USD
BERGER FRANKLIN M
Director
- 50000
 2.86 USD
1 year ago
Dec 16, 2022
Sell 134 K USD
BERGER FRANKLIN M
Director
- 50000
 2.67 USD
1 year ago
Dec 20, 2022
Sell 110 K USD
BERGER FRANKLIN M
Director
- 43617
 2.53 USD
1 year ago
Dec 21, 2022
Sell 91.3 K USD
BERGER FRANKLIN M
Director
- 37889
 2.41 USD
1 year ago
Dec 21, 2022
Sell 83.1 K USD
BERGER FRANKLIN M
Director
- 34334
 2.42 USD
1 year ago
Dec 30, 2022
Bought 21.6 K USD
Wood David S.
Chief Financial Officer
+ 8302
 2.6 USD
2 years ago
Oct 27, 2022
Bought 2.25 M USD
BIOTECH GROWTH N V
Director
+ 500000
 4.5022 USD
2 years ago
Oct 26, 2022
Bought 5.97 M USD
BIOTECH GROWTH N V
Director
+ 1500000
 3.979 USD
2 years ago
Jul 18, 2022
Bought 947 K USD
BB BIOTECH AG
director:
+ 300000
 3.1558 USD
2 years ago
Jul 18, 2022
Bought 947 K USD
BIOTECH GROWTH N V
10 percent owner
+ 300000
 3.1558 USD
2 years ago
Jul 15, 2022
Bought 757 K USD
BIOTECH GROWTH N V
10 percent owner
+ 241665
 3.1316 USD
2 years ago
Jul 14, 2022
Bought 969 K USD
BIOTECH GROWTH N V
10 percent owner
+ 347204
 2.7921 USD
2 years ago
Jul 14, 2022
Bought 969 K USD
BB BIOTECH AG
director:
+ 347204
 2.7921 USD
2 years ago
Jun 30, 2022
Bought 14.5 K USD
Parkinson David Ross
Chief Executive Officer
+ 4887
 2.958 USD
2 years ago
Apr 27, 2022
Sell 147 K USD
BB BIOTECH AG
director:
- 25100
 5.8536 USD
2 years ago
Apr 27, 2022
Sell 147 K USD
BIOTECH GROWTH N V
10 percent owner
- 25100
 5.8536 USD
3 years ago
Aug 18, 2021
Bought 2.22 M USD
BIOTECH GROWTH N V
10 percent owner
+ 250000
 8.8752 USD
3 years ago
Feb 22, 2021
Bought 1.54 M USD
BERGER FRANKLIN M
Director
+ 57000
 27 USD
20 years ago
Dec 03, 2003
Sell 94.3 K USD
CROOKE STANLEY T
Director
- 5000
 18.865 USD
20 years ago
Dec 02, 2003
Sell 175 K USD
CROOKE STANLEY T
Director
- 9500
 18.4279 USD
20 years ago
Dec 01, 2003
Sell 81.4 K USD
CROOKE STANLEY T
Director
- 4500
 18.0856 USD
20 years ago
Nov 26, 2003
Sell 93.9 K USD
CROOKE STANLEY T
Director
- 5300
 17.7189 USD
20 years ago
Nov 25, 2003
Sell 148 K USD
CROOKE STANLEY T
Director
- 8401
 17.6536 USD
20 years ago
Nov 24, 2003
Sell 14.4 K USD
CROOKE STANLEY T
Director
- 823
 17.5414 USD
21 years ago
Nov 21, 2003
Sell 180 K USD
CROOKE STANLEY T
Director
- 10104
 17.8367 USD
7. News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 16 hours ago
ATTENTION ESSA Pharma Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. accesswire.com - 2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 2 days ago
EPIX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ESSA Pharma Inc. NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. accesswire.com - 2 days ago
ESSA Pharma Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - EPIX NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. accesswire.com - 4 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 4 days ago
Lost Money on ESSA Pharma Inc.(EPIX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. accesswire.com - 4 days ago
EPIX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ESSA Pharma Inc. NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. accesswire.com - 5 days ago
EPIX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your ESSA Pharma Inc. investment NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. accesswire.com - 1 week ago
EPIX STOCK ALERT: Levi & Korsinsky Notifies ESSA Pharma Inc. Investors of an Ongoing Investigation NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. accesswire.com - 1 week ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ESSA Pharma Inc. (EPIX) and Encourages Shareholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESSWIRE / November 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:EPIX). Investors who purchased ESSA securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/EPIX. accesswire.com - 1 week ago
EPIX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ESSA Pharma Inc. NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens. accesswire.com - 1 week ago
8. Profile Summary

ESSA Pharma Inc. EPIX

image
COUNTRY CA
INDUSTRY Biotechnology
MARKET CAP $ 76.3 M
Dividend Yield 0.00%
Description ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Contact 999 West Broadway, Vancouver, BC, V5Z 1K5 https://www.essapharma.com
IPO Date March 13, 2015
Employees 50
Officers Dr. David Ross Parkinson M.D. President, Chief Executive Officer & Director Dr. Alessandra Cesano M.D., Ph.D. Chief Medical Officer & Executive Vice President Mr. David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA Chief Financial Officer Mr. Peter A. Virsik M.B.A., M.S. Executive Vice President & Chief Operating Officer Chandtip Chandhasin Executive Erica Osbourne Executive Erin Rudsinski Executive Loleta Harris Executive Neil Thapar Executive Nkengyal Barber Executive